FORA Capital’s Keros Therapeutics KROS Stock Holding History

FORA Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,480	Closed	-$561K	–	460
2024 Q1	$561K	Buy	+8,480	New	+$503K	0.05%	312

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

FORA Capital's KROS Position: Q2 2024 in Review

FORA Capital sold out of Keros Therapeutics (KROS) in Q2 2024, closing a stake of 8,480 shares — an estimated $561K sold.

FORA Capital first reported a position in KROS in Q1 2024 and held it in 1 quarter. The position peaked at $561K in Q1 2024. 152 funds tracked by Wall St. Rank hold KROS as of Q2 2024.

FORA Capital reported no remaining Keros Therapeutics position as of Q2 2024 after selling out during the quarter.
FORA Capital sold 8,480 Keros Therapeutics shares in Q2 2024, an estimated $561K.
FORA Capital first reported a position in Keros Therapeutics in Q1 2024 and held it in 1 quarter.
FORA Capital's Keros Therapeutics position peaked at $561K in Q1 2024.
152 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2024.

Based on FORA Capital's 13F filing for Q2 2024, filed 13 Aug 2024.